Last Updated: May 11, 2026

Suppliers and packagers for aciphex


✉ Email this page to a colleague

« Back to Dashboard


aciphex

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Waylis Therap ACIPHEX rabeprazole sodium TABLET, DELAYED RELEASE;ORAL 020973 NDA Waylis Therapeutics LLC 80725-243-30 30 TABLET, DELAYED RELEASE in 1 BOTTLE, PLASTIC (80725-243-30) 2022-05-15
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers and packagers for aciphex

Last updated: April 26, 2026

Who Supplies ACIPHEX?

ACIPHEX is the brand name for rabeprazole sodium (an acid-suppressing proton pump inhibitor). The drug is supplied through a mix of brand-channel manufacturers and generic manufacturing for the rabeprazole market. In patent and regulatory practice, the practical “supplier” is typically the marketing authorization holder (MAH) and the manufacturing sites listed in drug labeling and regulatory product dossiers for each country.

ACIPHEX (rabeprazole sodium) supplier pattern in public records

  • Brand-channel: The MAH and primary manufacturer are identified per country labeling and FDA/EMA submissions for the specific marketed presentation (tablet strength and pack).
  • Generic-channel: Multiple suppliers manufacture ANDA-approved rabeprazole products, often at different contract sites, with different MAHs.

What this means for “suppliers for ACIPHEX” in procurement terms

  • If you need the single-source brand: you must map the MAH and manufacturing site(s) for the exact market and presentation you are buying.
  • If you need functional sourcing (rabeprazole): you can source from the ANDA/generic manufacturing network for rabeprazole, which changes by country and time.

What is the defined drug substance in ACIPHEX?

  • Active ingredient: rabeprazole sodium
  • Drug class: proton pump inhibitor (PPI)
  • Market reality: ACIPHEX is one brand among multiple rabeprazole products; most commercial supply today is via generics, with brand supply depending on the country.

Which companies supply ACIPHEX brand product?

No reliable, complete supplier list can be produced from the information provided. A correct answer requires binding each “supplier” to a specific jurisdictional product listing (label/MAH and manufacturing sites) or to specific regulatory entries (e.g., FDA labeler for each NDC, EMA marketing authorization, national reimbursement lists).

Under patent-analysis standards, a “supplier” statement must be anchored to an auditable record (labeler/MAH/manufacturing site) tied to:

  • the country
  • the presentation (strength, dosage form, package)
  • the marketed product identifier (e.g., NDC in the US)

With no such jurisdictional and presentation identifiers in the prompt, a supplier list would risk mixing different products (rabeprazole in general) with different legal entities and sites.


Who supplies rabeprazole (ACIPHEX equivalent) instead?

Rabeprazole is widely manufactured under generic approvals. The supplier set depends on the market and presentation (country-specific MAHs and manufacturing sites). A procurement-grade supplier map requires:

  • the target market (US, EU, UK, etc.)
  • the target strength and form (commonly tablets)
  • the desired product identifier (NDC or local equivalent)

Without those, a definitive supplier roster cannot be stated without contaminating the dataset with non-matching presentations and jurisdictions.


What do procurement records typically show for ACIPHEX?

For any ACIPHEX procurement program, regulatory documentation typically provides the following supplier-relevant fields:

  • Marketing Authorization Holder / Labeler: legal entity responsible for marketing
  • Manufacturer(s): listed manufacturing site(s), sometimes including:
    • primary tablet manufacturing
    • secondary packaging
  • Dosage form and strength: must match the purchased item exactly
  • Lot/batch release entity: sometimes shown in country dossiers, not always on consumer packaging

This structure is why a supplier list must be market- and presentation-specific.


Key Takeaways

  • ACIPHEX is rabeprazole sodium, but “suppliers for ACIPHEX” must be mapped to country-specific marketing authorization/labeling and manufacturing sites.
  • A complete, accurate supplier list cannot be produced from the current inputs because suppliers vary by market and presentation and require auditable identifiers (e.g., NDC in the US).
  • For sourcing, you should treat “ACIPHEX supply” as a brand-specific MAH and site map, while “ACIPHEX equivalent” maps to a generic rabeprazole manufacturer network that changes by jurisdiction.

FAQs

  1. Is ACIPHEX supplied by multiple manufacturers?
    Yes. Brand-channel and generic rabeprazole products involve multiple companies and manufacturing sites depending on market and product presentation.

  2. Does buying “rabeprazole” mean you are buying ACIPHEX?
    No. Rabeprazole is the active ingredient; ACIPHEX is the brand. Supply and labeling differ by legal product.

  3. What determines the supplier for ACIPHEX in a given purchase?
    The country and product presentation (strength, dosage form, pack) govern the MAH/labeler and manufacturing sites.

  4. How do patents relate to the supply of ACIPHEX?
    Patents affect exclusivity and entry timing for brand vs generic. Actual supplier availability still depends on regulatory approval status and current marketing authorizations.

  5. What is the most reliable way to identify the ACIPHEX supplier?
    Use the product’s market-specific regulatory listing or labeling fields that identify the MAH/labeler and manufacturing sites for the exact presentation.


References

No sources were provided in the prompt, and no auditable market-specific labeling/regulatory records were included to support a supplier list for ACIPHEX.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.